Untangling the ErbB signalling network

By Y. Yarden, M. Sliwkowski. Nature reviews. Molecular cell biology, 2001

7,035 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/0661d1ca1286e89d8862eacc81bd178d28f53171

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Moasser
2. M. Lacouture
3. Carlos L. Arteaga
4. Y. Yarden
5. Matthias Mann
6. J. Baselga
7. Waltraud X. Schulze
8. Lei Deng

In Oncology

1. M. Moasser
2. S. Rosenberg
3. M. Lacouture
4. N. Hynes
5. J. Baselga
6. Matthias Mann
7. J. Engelman
8. C. Blobel

In Radiology, Nuclear Medicine and Imaging

1. M. Moasser
2. M. Lacouture
3. N. Hynes
4. J. Baselga
5. Matthias Mann
6. C. Blobel
7. Carlos L. Arteaga
8. Lei Deng

Citations in the corpus

• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (2008, background): “Activation of the ErbB/HER network is tightly regulated throughout development and in the adult (6, 23).”
• The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (2007, background): “Readers are referred to several recent excellent reviews of HER family signaling and functions (Mendelsohn and Baselga, 2000; Olayioye et al., 2000; Prenzel et al., 2001; Yarden and Sliwkowski, 2001; Barnes and Kumar, 2004).”
• Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands (2004, background): “The epidermal growth factor receptor (EGFR) signaling pathway has critical functions in development and in diseases such as cancer (Yarden and Sliwkowski, 2001).”
• Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. (2009, background): “These proteins are capable of forming heterodimers and homodimers, which activate signal transduction pathways that regulate many cellular processes, including growth, proliferation, and survival (1).”
• A quantitative protein interaction network for the ErbB receptors using protein microarrays (2006, background): “Interestingly, over-expression, gene amplification, or overactivation of EGFR and ErbB2 are frequently observed in human cancers 25–30 , whereas there is no evidence for gene amplification of ErbB3, and overexpression is limited 1 .”
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009, background): “jpg" NDATA ITEM> ]> Members of the epidermal growth factor family of transmembrane receptors (Erbb family) are potent mediators of normal cell growth and developmen”
• Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011, neutral): “org january 12, 2012 118 signaling to the greatest extent possible.(9,27) Although the number of patients who had received prior adjuvant or neoadjuvant chemotherapy with trastuzumab was small, the progression-free survival benefit of pertuzumab plus trastuzumab plus docetaxel therapy in those patie”